DDInter1763 DDInter156
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in February 2011. Many guidelines recommend the use of ARBs as first-line therapy when initiating antihypertensive therapy and indicate that the clinical efficacy of ARBs is comparable to angiotensin-converting enzyme (ACE) inhibitors that are also used as first-line treatment for hypertension. Azilsartan medoxomil is marketed under the brand name Edarbi. It is used to treat hypertension as monotherapy or in combination with other antihypertensive drugs. It is also available in a combination product with [chlorthalidone]. As hypertension is a major risk factor for cardiovascular disease, early management of hypertension has several implications on patients' survival rate and quality of life in the future. Lowering blood pressure is associated with a reduced risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil is thus speculated to lower mortality rates and the onset of cardiovascular disease. Although there is no clinical significance yet determined, azilsartan medoxomil may have potential off-label uses in patients with a history of myocardial infarction or heart failure.
Temsirolimus {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Azilsartan medoxomil
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Temsirolimus {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Olmesartan
Olmesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Tasosartan
Tasosartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olmesartan
Olmesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Temsirolimus {u} (Compound) causes {v} (Side Effect) Skin disorder
Skin disorder {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Temsirolimus {u} (Compound) downregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is upregulated by {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azilsartan medoxomil
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} (Compound) causes {v} (Side Effect) Hyperuricaemia
Hyperuricaemia {u} (Side Effect) is caused by {v} (Compound) Azilsartan medoxomil
Temsirolimus {u} (Compound) upregulates {v} (Gene) NVL
NVL {u} (Gene) is downregulated by {v} (Compound) Candesartan
Candesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Temsirolimus (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Azilsartan medoxomil (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Temsirolimus (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Olmesartan (Compound) and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tasosartan (Compound) and Tasosartan (Compound) resembles Azilsartan medoxomil (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Temsirolimus (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Temsirolimus (Compound) downregulates TATDN2 (Gene) and TATDN2 (Gene) is upregulated by Candesartan (Compound) and Candesartan (Compound) resembles Azilsartan medoxomil (Compound)
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Azilsartan medoxomil
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Azilsartan medoxomil (Compound)
Temsirolimus (Compound) upregulates NVL (Gene) and NVL (Gene) is downregulated by Candesartan (Compound) and Candesartan (Compound) resembles Azilsartan medoxomil (Compound)